10-Q: Organon & Co. Q2 2026 Earnings: Acquisition by Sun Pharma Nears Completion

Organon & Co. reported a 2% decrease in Q2 2026 sales, impacted by product mix and foreign exchange, while progressing towards its acquisition by Sun Pharma.

Summary

• Organon & Co. reported total sales of $1.558 billion for the three months ended June 30, 2026, a decrease of 2% compared to the same period in 2025. Excluding foreign exchange impacts, sales decreased by 5%.
• For the six months ended June 30, 2026, total sales were $3.018 billion, a decrease of 3% compared to 2025. Excluding foreign exchange impacts, sales decreased by 7%.
• The company is nearing completion of its acquisition by Sun Pharmaceutical Industries Limited, with stockholder approval received and an expected closing in early 2027.
• Key product sales declines were noted in Ontruzant, Singulair, and Jada (due to divestiture).
• Sales increases were observed in Hadlima, Zetia/Vytorin, and Emgality.
• Restructuring costs of $31 million were incurred in the first half of 2026 related to optimizing R&D and manufacturing operations.
• Net income for the three months ended June 30, 2026, was $108 million, down from $145 million in the prior year. For the six months ended June 30, 2026, net income was $254 million, up from $232 million in the prior year.
• The company reported $1.132 billion in cash and cash equivalents as of June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to declining sales and net income for the quarter, despite progress on the acquisition and some product growth.

Positives

• Hadlima sales increased significantly (59% for Q2, 51% for H1) due to stronger demand in the US and Puerto Rico.
• Zetia/Vytorin sales increased (16% for Q2, 8% for H1) driven by higher demand in China.
• Emgality sales showed strong growth (27% for Q2, 45% for H1) due to increased demand in international markets.
• The acquisition by Sun Pharma is progressing, with stockholder approval obtained.
• Cash and cash equivalents increased to $1.132 billion as of June 30, 2026.
• Working capital improved to $2.50 billion as of June 30, 2026.
• The company is in compliance with its senior credit agreement financial covenants.
• Material weaknesses in internal control over financial reporting have been remediated as of June 30, 2026.

Negatives

• Worldwide sales decreased by 2% for the three months ended June 30, 2026, and 3% for the six months ended June 30, 2026.
• Ontruzant sales declined significantly (81% for Q2, 77% for H1) due to lower tendered volume in Brazil.
• Singulair sales decreased substantially (27% for Q2, 37% for H1) due to less favorable medical guidelines, supply constraints, and price reductions.
• Nexplanon sales declined (4% for Q2, 12% for H1) due to decreased physician demand in the US and uncertainty around federal funding.
• Jada sales ceased following its divestiture in January 2026.
• Restructuring costs of $31 million were incurred in the first half of 2026.
• Net income for the three months ended June 30, 2026, decreased to $108 million from $145 million in the prior year.
• Several legal proceedings are ongoing, including product liability and securities litigation.

Risks

• The proposed transaction with Sun Pharma may not be completed on the anticipated terms or at all.
• Competing offers or acquisition proposals for Organon could emerge.
• Failure to satisfy closing conditions for the Sun Pharma transaction, including regulatory approvals.
• Expanded brand and class competition in the markets where Organon operates.
• Trade protection measures, tariffs, trade sanctions, or similar restrictions.
• Changes in U.S. and foreign governmental funding allocations.
• The impact of global business, political, and macroeconomic conditions, including inflation and recessionary pressures.
• Competition from generic products as Organon's products lose patent protection.

Future Outlook

The company expects the expansion of Nexplanon use from its new five-year label approval to begin offsetting reinsertion headwinds in the second half of 2026. The EU application for Nexplanon's five-year duration is under review with potential approval in 2027. Mercilon Combination Tablets received regulatory approval in Japan for dysmenorrhea treatment. Vtama is anticipated to launch in certain international markets in 2026 and beyond, subject to approvals. Volume-based procurement in China is expected to continue negatively impacting the general medicines portfolio for the next several quarters.

Management Comments

• The company is adapting its business and sales strategies to address changing market conditions, including ongoing regional conflicts, tariffs, tax law changes, and regulatory uncertainty.
• Strategies may include implementing or continuing to assess product discount programs and wholesaler inventory levels.
• Management has concluded that material weaknesses in internal control over financial reporting have been remediated as of June 30, 2026.

Industry Context

StockSavvy.ai notes that Organon's Q2 2026 results reflect ongoing challenges in the pharmaceutical sector, including pricing pressures, generic competition, and evolving regulatory landscapes. The planned acquisition by Sun Pharma suggests a strategic shift or consolidation within the industry.

Comparison to Industry Standards

• Organon's revenue decline of 2% for the quarter is slightly worse than the projected global pharmaceutical market growth rate of approximately 3-5% for 2026, indicating company-specific challenges.
• The significant increase in Hadlima sales (59% YoY) outpaces the typical growth for established biosimilars, suggesting strong market penetration or competitive advantage.
• The decline in Singulair sales (27% YoY) is a common trend for older branded drugs facing guideline changes and generic competition, a pattern seen across the industry for similar products.
• The company's focus on women's health and biosimilars aligns with growing market segments, but competitive pressures are evident across these areas.

Legal Proceedings

• Merck is a defendant in product liability lawsuits involving Fosamax (alendronate sodium), with approximately 498 cases in Federal court, 1,478 in New Jersey state court, one in Pennsylvania state court, and 149 in California state court, alleging femur fractures and/or other bone injuries.
• Merck is a defendant in lawsuits relating to Nexplanon and Implanon, with two filed product liability actions in the Northern District of Ohio and one matter in California state court.
• A stockholder lawsuit was filed on May 27, 2025, and another on July 8, 2025, alleging materially false and misleading statements regarding capital allocation and debt reduction strategies.
• Two stockholder derivative lawsuits were filed asserting breach of fiduciary duties arising from purportedly false and misleading statements.
• Organon made a voluntary self-disclosure to the SEC regarding an investigation into Nexplanon sales to certain wholesalers in the United States.
• Organon received Paragraph IV Certification Letters from Xiromed Pharma Espana, S.L. (Xiromed) regarding a generic version of Nexplanon, leading to a patent infringement lawsuit.
• Organon received Paragraph IV Certification Letters from Encube Ethical Private Limited (Encube), Mylan Pharmaceuticals, Inc. (Mylan), and Natco Pharma Limited (Natco) regarding generic versions of Vtama, and intends to defend its intellectual property rights.

Stakeholder Impact

• Shareholders are impacted by the pending acquisition by Sun Pharma at $14.00 per share in cash.
• Employees may be impacted by restructuring initiatives, including a 3% headcount reduction in R&D and manufacturing.
• Customers and business partners may be affected by changes in sales strategies, including product discount programs and inventory management.
• Creditors are subject to the company's compliance with senior credit agreement financial covenants.

Next Steps

• Complete the acquisition by Sun Pharmaceutical Industries Limited, expected in early 2027.
• Launch Pyzchiva in Canada in the second half of 2026.
• Launch Epyztek in Australia in the second half of 2026.
• Estimate commercial sales of Miudella in the United States in late 2026.
• Anticipate favorable offsetting of Nexplanon reinsertion headwinds beginning in the second half of 2026.
• Continue to adapt business and sales strategies to address changing market and regulatory landscapes.
• Continue to separate supply chain through planned exits from supply agreements with Merck through 2031.

Key Dates

Recommendation

The pending acquisition by Sun Pharma at a fixed price provides a floor for the stock. However, the ongoing sales decline and net income decrease in the current quarter, coupled with ongoing legal risks, warrant a hold recommendation until the acquisition closes or significant positive operational changes occur.

Keywords

Organon, Pharmaceuticals, Womens Health, Biosimilars, General Medicines, Sun Pharma Acquisition, Form 10-Q, Financial Results